


## Data Sheet

[WWW.UREIKO.COM](http://WWW.UREIKO.COM)

Global Supplier of Chemical Probes, Inhibitors & Agonists

<b>Product Name</b>	:IPI-549
<b>Cat.No.</b>	:URK-V596
<b>CAS No.</b>	:1693758-51-8
<b>Molecular Formula</b>	:C <sub>30</sub> H <sub>24</sub> N <sub>8</sub> O <sub>2</sub>
<b>Molecular Weight</b>	:528.564
<b>Target</b>	:PI3K
<b>Solubility</b>	:15mM in DMSO



### Biological Activity

Eganelisib (IPI-549) is a potent, highly selective, orally active inhibitor of PI3K $\gamma$  with IC<sub>50</sub> of 16 nM, displays >100-fold selectivity over other lipid and protein kinases (PI3K $\alpha$  IC<sub>50</sub>=3.2  $\mu$ M, PI3K $\beta$  IC<sub>50</sub>=3.5  $\mu$ M, PI3K $\delta$  IC<sub>50</sub>>8.4  $\mu$ M). Eganelisib (IPI-549) demonstrates excellent PI3K $\gamma$  potency (IC<sub>50</sub>=1.2 nM) and selectivity against other Class I PI3K isoforms (>146-fold) in cellular phospho-AKT assays, dose dependently inhibits PI3K $\gamma$  dependent bone marrow-derived macrophage (BMDM) migration.

Eganelisib (IPI-549) demonstrates favorable pharmacokinetic properties and robust inhibition of PI3K- $\gamma$  mediated neutrophil migration in vivo.

### References

1. Evans CA, et al. ACS Med Chem Lett. 2016 Jul 22;7(9):862-7.
2. De Henau O, et al. Nature. 2016 Nov 17;539(7629):443-447.

*Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!*

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

[jack@ureiko.com](mailto:jack@ureiko.com)